<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<teiCorpus xmlns="http://www.tei-c.org/ns/1.0" xmlns:ext="http://exslt.org/common" xmlns:ng="http://relaxng.org/ns/structure/1.0" xmlns:uuid="xalan://java.util.UUID" xml:space="preserve">
	<teiHeader type="family">
		<fileDesc>
			<titleStmt>
				<title>Patent family information</title>
				<funder/>
				<sponsor/>
			</titleStmt>
			<publicationStmt>
				<authority/>
				<availability status="restricted"/>
			</publicationStmt>
			<sourceDesc>
				<bibl type="patent-family">
					<idno type="family-id">12742447</idno></bibl><listBibl type="priority-claims"><biblStruct status="application" subtype="docdb" type="patent"><monogr><authority><orgName type="national">JP</orgName></authority><idno type="docNumber">4626791</idno><imprint><classCode scheme="kindCode">A</classCode><date>19910312</date></imprint></monogr></biblStruct><biblStruct status="application" subtype="epodoc" type="patent"><monogr><idno type="docNumber">JP4626791A</idno></monogr></biblStruct><biblStruct status="application" subtype="docdb" type="patent"><monogr><authority><orgName type="national">JP</orgName></authority><idno type="docNumber">46267/91</idno><imprint><date>19910312</date></imprint></monogr></biblStruct></listBibl>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<textClass type="patent-classifications"><classCode scheme="ICO"><orgName type="classification-scheme-office">EPO</orgName><term type="classification-symbol">M07D495/04</term></classCode><classCode scheme="EC"><orgName type="classification-scheme-office">EPO</orgName><term type="classification-symbol">C07D495/04</term></classCode><classCode scheme="ICO"><orgName type="classification-scheme-office">EPO</orgName><term type="classification-symbol">M07D495/04+333B+221B</term></classCode>
			</textClass>
		</profileDesc>
	</teiHeader>
	<teiCorpus>
		<teiHeader type="application">
			<fileDesc>
				<titleStmt>
					<title>Patent application information</title>
				</titleStmt>
				<publicationStmt>
					<authority/>
				</publicationStmt>
				<sourceDesc>
					<biblStruct status="application" subtype="docdb" type="patent"><idno type="is-representative">NO</idno><monogr><authority><orgName type="regional">EP</orgName></authority><idno type="docNumber">92301900</idno><imprint><classCode scheme="kindCode">A</classCode><date>19920305</date></imprint></monogr></biblStruct><biblStruct status="application" subtype="epodoc" type="patent"><monogr><idno type="is-representative">NO</idno><idno type="docNumber">EP92301900A</idno></monogr></biblStruct><list type="additional-bibliographic-information"><item type="parties"><listPerson type="inventors"><person role="inventor" type="epo"><persName>HAYASHI HIROAKI</persName><residence><address><country type="national">JP</country></address></residence></person><person role="inventor" type="epo"><persName>KURODA TAKESHI</persName><residence><address><country type="national">JP</country></address></residence></person><person role="inventor" type="epo"><persName>MIWA YOSHIKAZU</persName><residence><address><country type="national">JP</country></address></residence></person><person role="inventor" type="epo"><persName>NAKAJIMA HIROSHI</persName><residence><address><country type="national">JP</country></address></residence></person><person role="inventor" type="epo"><persName>OHMORI KENJI</persName><residence><address><country type="national">JP</country></address></residence></person><person role="inventor" type="epo"><persName>SUZUKI FUMIO</persName><residence><address><country type="national">JP</country></address></residence></person><person role="inventor" type="intermediate"><persName>HAYASHI, HIROAKI</persName></person><person role="inventor" type="intermediate"><persName>KURODA, TAKESHI</persName></person><person role="inventor" type="intermediate"><persName>MIWA, YOSHIKAZU</persName></person><person role="inventor" type="intermediate"><persName>NAKAJIMA, HIROSHI</persName></person><person role="inventor" type="intermediate"><persName>OHMORI, KENJI</persName></person><person role="inventor" type="intermediate"><persName>SUZUKI, FUMIO</persName></person><person role="inventor" type="original"><persName>HAYASHI, HIROAKI</persName><residence><address><addrLine>151-12, Shimotogari, Nagaizumi-cho</addrLine><settlement>Sunto-gun, Shizuoka-ken</settlement><country type="national">JP</country></address></residence></person><person role="inventor" type="original"><persName>KURODA, TAKESHI</persName><residence><address><addrLine>1407, Shimotogari, Nagaizumi-cho</addrLine><settlement>Sunto-gun, Shizuoka-ken</settlement><country type="national">JP</country></address></residence></person><person role="inventor" type="original"><persName>MIWA, YOSHIKAZU</persName><residence><address><addrLine>1188, Shimotogari, Nagaizumi-cho</addrLine><settlement>Sunto-gun, Shizuoka-ken</settlement><country type="national">JP</country></address></residence></person><person role="inventor" type="original"><persName>NAKAJIMA, HIROSHI</persName><residence><address><addrLine>410-1, Nameri, Nagaizumi-cho</addrLine><settlement>Sunto-gun, Shizuoka-ken</settlement><country type="national">JP</country></address></residence></person><person role="inventor" type="original"><persName>OHMORI, KENJI</persName><residence><address><addrLine>2-14-3, Fuyodai</addrLine><settlement>Mishima-shi, Shizuoka-ken</settlement><country type="national">JP</country></address></residence></person><person role="inventor" type="original"><persName>SUZUKI, FUMIO</persName><residence><address><addrLine>18-4, Fujimidai</addrLine><settlement>Mishima-shi, Shizuoka-ken</settlement><country type="national">JP</country></address></residence></person></listPerson><list type="applicants"><item type="epo"><name>KYOWA HAKKO KOGYO KK</name><address><country type="national">JP</country></address></item><item type="intermediate"><name>KYOWA HAKKO KOGYO CO., LTD.</name></item></list></item><item type="designation-of-states"><list type="designation-epc"><item type="regional"><country>AT</country><country>BE</country><country>CH</country><country>DE</country><country>DK</country><country>ES</country><country>FR</country><country>GB</country><country>GR</country><country>IT</country><country>LI</country><country>LU</country><country>MC</country><country>NL</country><country>PT</country><country>SE</country></item></list></item></list>
				</sourceDesc>
			</fileDesc>
			<profileDesc>
				<langUsage><language ident="en">en</language></langUsage><textClass type="classifications-ipcr"><classCode scheme="ipcr">A61P   3/00        20060101CLI20051220RMJP        </classCode><classCode scheme="ipcr">A61K  31/44        20060101AFI20051220RMJP        </classCode><classCode scheme="ipcr">A61K  31/4353      20060101CLI20051220RMJP        </classCode><classCode scheme="ipcr">A61P  37/00        20060101CLI20051220RMJP        </classCode><classCode scheme="ipcr">A61K  31/4365      20060101ALI20051220RMJP        </classCode><classCode scheme="ipcr">C07D 495/00        20060101C I20051008RMEP        </classCode><classCode scheme="ipcr">A61P  37/06        20060101ALI20051220RMJP        </classCode><classCode scheme="ipcr">A61K  31/44        20060101CFI20051220RMJP        </classCode><classCode scheme="ipcr">A61P   3/00        20060101ALI20051220RMJP        </classCode><classCode scheme="ipcr">A61P  19/10        20060101ALI20051220RMJP        </classCode><classCode scheme="ipcr">A61P  37/02        20060101ALI20051220RMJP        </classCode><classCode scheme="ipcr">A61P  19/00        20060101CLI20051220RMJP        </classCode><classCode scheme="ipcr">A61P  43/00        20060101ALI20051220RMJP        </classCode><classCode scheme="ipcr">A61P  43/00        20060101CLI20051220RMJP        </classCode><classCode scheme="ipcr">C07D 495/04        20060101A I20051008RMEP        </classCode></textClass>
			</profileDesc>
		</teiHeader>
		<TEI>
			<teiHeader type="publication">
				<fileDesc>
					<titleStmt>
						<title type="invention-title" xml:lang="de">Thienopyridinderivate und diese enthaltende pharmazeutische Zubereitungen</title>
						<title type="invention-title" xml:lang="en">Thienopyridine derivatives and pharmaceutical compositions containing them</title>
						<title type="invention-title" xml:lang="fr">Dérivés de la thiénopyridine et compositions pharmaceutiques les contenant</title>
					</titleStmt>
					<publicationStmt>
						<authority/>
					</publicationStmt>
					<notesStmt/>
					<sourceDesc>
						<biblStruct status="publication" subtype="docdb" type="patent"><monogr><authority><orgName type="regional">EP</orgName></authority><idno type="docNumber">0505058</idno><imprint><classCode scheme="kindCode">B1</classCode><date>19970521</date></imprint></monogr></biblStruct><biblStruct status="publication" subtype="epodoc" type="patent"><monogr><idno type="docNumber">EP0505058B1</idno></monogr>
						</biblStruct>
					</sourceDesc>
				</fileDesc>
			</teiHeader>
			<facsimile/>
			<text>
				<front/>
				<group>
					<text>
						<body>
							<div type="claims" xml:lang="de">
								<div n="0" type="claim">
									<p xml:id="_f0590">Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, MC, NL, PT, SE</p>
								</div>
								<div n="1" type="claim">
									<p xml:id="_5abd0">Thienopyridinderivat der Formel (I): 
in der: new
			<list type="simple">
				<item>einer der Reste A und B eine Gruppe der Formel -S- darstellt, und der andere eine Gruppe der Formel -CH= bedeutet; </item>
				<item>R ein Wasserstoffatom oder einen C1-C6-Alkylrest darstellt, und </item>
				<item>Z eine Pyridylgruppe bedeutet; oder </item>
			</list> 
ein pharmazeutisch verträgliches Säureadditions- oder Metallsalz davon. </p>
			</div>
			<div n="2" type="claim">
				<p xml:id="_28ca2">Verbindung nach Anspruch 1, wobei in der Formel A eine Gruppe der Formel -S- ist, und B eine Gruppe der Formel -CH= ist. </p>
			</div>
			<div n="3" type="claim">
				<p xml:id="_c2188">4-(n-Butyl)-4,5-dihydro-7-hydroxy-5-oxo-N-(4-pyridyl)thieno-[3,2-b]-pyridin-6-carbonsäureamid und seine pharmazeutisch verträglichen Säureadditions- und Metallsalze. </p>
			</div>
			<div n="4" type="claim">
				<p xml:id="_44c27">Arzneimittel, umfassend eine Verbindung oder ein Salz nach einem der Ansprüche 1-3 im Gemisch mit einem pharmazeutisch verträglichen Träger oder Verdünnungsmittel. </p>
			</div>
			<div n="5" type="claim">
				<p xml:id="_1c0cd">Immunregulierende pharmazeutische Zubereitung, umfassend eine Verbindung oder ein Salz nach einem der Ansprüche 1-3 als Immunregulator. </p>
			</div>
			<div n="6" type="claim">
				<p xml:id="_857b2">Pharmazeutische Zubereitung gegen Osteoporose, umfassend eine Verbindung oder ein Salz nach einem der Ansprüche 1-3 als Mittel gegen Osteoporose. </p>
			</div>
			<div n="7" type="claim">
				<p xml:id="_013ee">Zur Verwendung als Immunregulator: Verbindung oder Salz nach einem der Ansprüche 1-3 . </p>
			</div>
			<div n="8" type="claim">
				<p xml:id="_70f66">Zur Verwendung als Mittel gegen Osteoporose: Verbindung oder Salz nach einem der Ansprüche 1-3 . </p>
			</div>
			<div n="9" type="claim">
				<p xml:id="_96384">Verbindung oder Salz nach einem der Ansprüche 1 bis 3 zur Verwendung als Arzneimittel. </p>
			</div>
			<div n="10" type="claim">
				<p xml:id="_8af07">Verwendung einer Verbindung oder eines Salzes nach einem der Ansprüche 1 bis 3 zur Herstellung eines Immunregulators oder eines Mittels gegen Osteoporose. </p>
			</div>
			<div n="11" type="claim">
				<p xml:id="_486c4">Verwendung einer Verbindung oder eines Salzes nach einem der Ansprüche 1 bis 3 zur Herstellung eines Arzneimittels zur Unterdrückung des Immunsystems durch Inhibierung der Antikörperbildung. </p>
			</div>
			<div n="0" type="claim">
				<p xml:id="_2916d">Patentansprüche für folgende Vertragsstaaten : ES, GR</p>
			</div>
			<div n="1" type="claim">
				<p xml:id="_ca8a9">Verfahren zur Herstellung eines Thienopyridinderivats der Formel (I): 
in der: 
					<list type="simple">
						<item>einer der Reste A und B eine Gruppe der Formel -S- darstellt, und der andere eine Gruppe der Formel -CH= bedeutet; </item>
						<item>R ein Wasserstoffatom oder einen C1-C6-Alkylrest darstellt, und </item>
						<item>Z eine Pyridylgruppe bedeutet; das die Umsetzung einer Verbindung der Formel (II): 
mit einem Amin der Formel (III) 
H2N-Z 
umfaßt, wobei in den Formeln (II) und (III) A, B, R und Z wie vorstehend definiert sind, und L ein Halogenatom, ein Alkoxy-, Aryloxy-, Alkanoyloxy- oder ein Aroyloxyrest ist. </item>
					</list>
				</p>
			</div>
			<div n="2" type="claim">
				<p xml:id="_ac4bb">Verfahren nach Anspruch 1, wobei die Umsetzung in Gegenwart einer Base durchgeführt 
			wird. </p>
			</div>
			<div n="3" type="claim">
				<p xml:id="_e32e2">Verfahren nach Anspruch 1 oder 2, wobei die Umsetzung bei einer Temperatur im Bereich von <measure type="interval"><num atLeast="-30">-30</num> bis <num atMost="200">200</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>, bevorzugt <measure type="interval"><num atLeast="-10">-10</num> bis <num atMost="100">100</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>, durchgeführt wird. </p></div><div n="4" type="claim"><p xml:id="_2c42f">Verfahren nach einem der Ansprüche 1-3, wobei die Verbindung der Formel (I) als pharmazeutisch verträgliches Säureadditions- oder Metallsalz gewonnen wird oder anschließend darin umgewandelt wird.  </p>
		 	</div>
			<div n="5" type="claim">
				<p xml:id="_ca0f6">Verfahren nach einem der Ansprüche 1-4, wobei in den Formeln A eine Gruppe der Formel -S- ist, und B eine Gruppe der Formel -CH= ist. </p></div><div n="6" type="claim"><p xml:id="_fdbf0">Verfahren nach einem der Ansprüche 1-4, wie es auf die Herstellung der Verbindung 4-(n-Butyl)-4,5-dihydro-7-hydroxy-5-oxo-N-(4-pyridyl)thieno-[3,2-b]-pyridin-6-carbonsäureamid oder seiner pharmazeutisch verträglichen Säureadditions- oder Metallsalze angewendet wird. </p>
			</div>
			<div n="7" type="claim"><p xml:id="_001a9">Verfahren nach einem der Ansprüche 1-6, das den weiteren Schritt des Mischens der Verbindung der Formel (I), gegebenenfalls nach deren Umwandlung in ein pharmazeutisch verträgliches Säureadditions- oder Metallsalz, mit einem pharmazeutisch verträglichen Träger oder Verdünnungsmittel umfaßt. </p>
			</div>
		</div>
		<div type="claims" xml:lang="en">
			<div n="0" type="claim">
				<p xml:id="_12d98">Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, MC, NL, PT, SE</p>
			</div>
			<div n="1" type="claim">
				<p xml:id="_5993c">A thienopyridine derivative of the formula (I): 
wherein: 
					<list type="simple">
						<item>one of A and B represents -S- and the other represents -CH=; </item>
						<item>R represents hydrogen or C1 - C6 alkyl; and </item>
						<item>Z represents pyridyl; or </item>
					</list> 
a pharmaceutically acceptable acid addition or metal salt thereof. 
				</p>
			</div>
			<div n="2" type="claim">
				<p xml:id="_0adfa">A Compound according to claim 1, wherein, in said formula, A is - S-, and B is -CH=. </p>
			</div>
			<div n="3" type="claim">
				<p xml:id="_5d855">4-(n-Butyl)-4,5-dihydro-7-hydroxy-5-oxo-N-(4-pyridyl)thieno[3,2-b]pyridine-6-carboxamide, and its pharmaceutically acceptable acid addition and metal salts. </p>
			</div>
			<div n="4" type="claim">
				<p xml:id="_b77c6">A pharmaceutical composition comprising a compound or salt as defined by any one of claims 1-3 in a admixture with a pharmaceutically acceptable carrier or diluent. </p>
			</div>
			<div n="5" type="claim">
				<p xml:id="_b5558">An immunoregulatory pharmaceutical preparation comprising as the immunoregulator a compound or salt according to any one of claims 1-3. </p>
			</div>
			<div n="6" type="claim">
				<p xml:id="_0c719">An antiosteoporosis pharmaceutical preparation comprising as the antiosteoporosis agent a compound or salt according to any one of claims 1-3.</p>
			</div>
			<div n="7" type="claim">
				<p xml:id="_a7182">For use as an immunoregulator: a compound or salt as claimed in any one of claims 1-3. </p>
			</div>
			<div n="8" type="claim">
				<p xml:id="_59739">For use as an antiosteoporosis agent: a compound or salt as claimed in any one of claims 1-3. </p>
			</div>
			<div n="9" type="claim">
				<p xml:id="_d904e">A compound or salt according to any one of claims 1 to 3 for use as a pharmaceutical. </p>
			</div>
			<div n="10" type="claim"><p xml:id="_345bd">Use of a compound or salt according to any one of claims 1 to 3 in the manufacture of an immunoregulator or an antiosteoporosis agent. </p>
			</div>
			<div n="11" type="claim">
				<p xml:id="_e174f">Use of a compound or salt according to any one of claims 1 to 3 in the manufacture of a medicament to suppress the immune system by inhibiting antibody production. </p>
			</div>
			<div n="0" type="claim">
				<p xml:id="_c9b01">Claims for the following Contracting States : ES, GR</p>
			</div>
			<div n="1" type="claim">
				<p xml:id="_05b08">A method for the preparation of a thiefiopyridine derivative of the formula (I): 
wherein: 
					<list type="simple">
						<item>one of A and B represents -S- and the other represents -CH=; </item>
						<item>R represents hydrogen or C1 - C6 alkyl; and </item>
						<item>Z represents pyridyl, which comprises reacting a compound of the formula II: 
with an amine of the formula [I] 
H2N - Z 
where in said formula II and III A, B, R and Z are as defined 
above, and L is halogen, alkoxy, aryloxy, alkanoyloxy or aroyloxy. </item>
					</list>
				</p>
			</div>
			<div n="2" type="claim">
				<p xml:id="_d8fb9">A method according to claim 1, wherein the reaction is carried out in the presence of a base. </p>
			</div>
			<div n="3" type="claim">
				<p xml:id="_9c42c">A method according to claim 1 or 2, wherein the reaction is performed at a temperature in the range <measure type="interval"><num atLeast="-30">-30</num> to <num atMost="200">200</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>, preferably <measure type="interval"><num atLeast="-10">-10</num> to <num atMost="100">100</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>. </p>
			</div>
			<div n="4" type="claim">
				<p xml:id="_f5b79">A method according to any one of claims 1-3, wherein the compound of formula I is recovered as or is subsequently converted into a pharmaceutically acceptable acid addition or metal salt. </p>
			</div>
			<div n="5" type="claim">
				<p xml:id="_a9001">A method according to any one of claims 1-4, wherein in said formulae A is -S-, and B is -CH=. </p>
			</div>
			<div n="6" type="claim">
				<p xml:id="_4e48b">A method according to any one of claims 1-4 as applied to the preparation of the compound 4-(n-butyl)-4,5-dihydro-7-hydroxy-5-oxo-N-(4-pyridyl)thieno[3,2-b]pyridine-6-carboxamide,or its pharmaceutically acceptable acid addition or metal salts. </p>
			</div>
			<div n="7" type="claim">
				<p xml:id="_2c10a">A method according to any one of claims 1-6, which comprises the further step of mixing the compound of formula I, optionally after conversion thereof into a pharmaceutically acceptable acid addition or metal salt, with a pharmaceutically acceptable carrier or diluent. </p>
			</div>
		</div>
		<div type="claims" xml:lang="fr">
			<div n="0" type="claim">
				<p xml:id="_8ee4d">Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, MC, NL, PT, SE</p>
			</div>
			<div n="1" type="claim">
				<p xml:id="_58c24">Dérivé de thiénopyridine, de formule (I) : 
dans laquelle l'un des symboles A et B représente un chaínon -S- et l'autre représente un chaínon -CH=, R représente un atome d'hydrogène ou un groupe alkyle en C1-C6, et Z représente un groupe pyridyle, ou sel de métal ou d'addition d'acide d'un tel dérivé, admissible en pharmacie. </p>
			</div>
			<div n="2" type="claim">
				<p xml:id="_c0bf8">Composé conforme à la revendication 1, dans lequel, dans ladite formule, A représente un chaínon -S- et B représente un chaínon -CH=. </p>
			</div>
			<div n="3" type="claim">
				<p xml:id="_39e22">4-(n-butyl)-4,5-dihydro-7-hydroxy-5-oxo-N-(4-pyridyl)thiéno[3,2-b]pyridine-6-carboxamide, et ses sels de métal ou d'addition d'acide, admissibles en pharmacie. </p>
			</div>
			<div n="4" type="claim">
				<p xml:id="_aa1bf">Composition pharmaceutique comprenant un composé ou un sel conforme à l'une des revendications 1 à 3, mélangé avec un véhicule ou un diluant admissible en pharmacie. </p>
			</div>
			<div n="5" type="claim">
				<p xml:id="_d610a">Préparation pharmaceutique immunorégulatrice, qui contient, comme agent immunorégulateur, un composé ou un sel conforme à l'une des revendications 1 à 3. </p>
			</div>
			<div n="6" type="claim">
				<p xml:id="_d01bb">Préparation pharmaceutiques anti-ostéoporose, qui contient, comme agent anti-ostéoporose, un composé ou un sel conforme à l'une des revendications 1 à 3. </p>
			</div>
			<div n="7" type="claim">
				<p xml:id="_6a6a6">Composé ou sel conforme à l'une des revendications 1 à 3, destiné à être utilisé comme agent immunorégulateur. </p>
			</div>
			<div n="8" type="claim">
				<p xml:id="_7a259">Composé ou sel conforme à l'une des revendications 1 à 3, destiné à être utilisé comme agent anti-ostéoporose. </p>
			</div>
			<div n="9" type="claim">
				<p xml:id="_50a91">Composé ou sel conforme à l'une des revendications 1 à 3, destiné à être utilisé comme agent pharmaceutique. </p>
			</div>
			<div n="10" type="claim">
				<p xml:id="_c3dbb">Utilisation d'un composé ou d'un sel conforme à l'une des revendications 1 à 3, pour la fabrication d'un agent anti-ostéoporose ou d'un agent immunorégulateur. </p>
			</div>
			<div n="11" type="claim">
				<p xml:id="_ba27f">Utilisation d'un composé ou d'un sel conforme à l'une des revendications 1 à 3, pour la fabrication d'un médicament immunodépresseur qui agit en inhibant la production d'anticorps. </p>
			</div>
			<div n="0" type="claim">
				<p xml:id="_7a840">Revendications pour les Etats contractants suivants : ES, GR</p>
			</div>
			<div n="1" type="claim">
				<p xml:id="_d1524">Procédé de préparation d'un dérivé de thiénopyridine, de formule (I) : 
dans laquelle l'un des symboles A et B représente un chaínon -S- et l'autre représente un chaínon -CH=, R représente un atome d'hydrogène ou un groupe alkyle en C1-C6, et Z représente un groupe pyridyle, qui comporte le fait de faire réagir un composé de formule (II) : 
avec une amine de formule (III) : H2N - Z dans lesquelles formules (II) et (III) A, B, R et Z ont les définitions indiquées ci-dessus et L représente un atome d'halogène ou un groupe alcoxy, aryloxy, alcanoyloxy ou aroyloxy. </p>
			</div>
			<div n="2" type="claim">
				<p xml:id="_e09cf">Procédé conforme à la revendication 1, dans lequel on effectue la réaction en présence d'une base. </p>
			</div>
			<div n="3" type="claim">
				<p xml:id="_65176">Procédé conforme à la revendication 1 ou 2, dans lequel on effectue la réaction à une température située dans l'intervalle allant de <measure type="interval"><num atLeast="-30">-30</num><measure type="TEMPERATURE" unit="°C">°C</measure> à <num atMost="200">200</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>, de préférence de <measure type="interval"><num atLeast="-10">-10</num><measure type="TEMPERATURE" unit="°C">°C</measure> à <num atMost="100">100</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>. </p>
			</div>
			<div n="4" type="claim">
				<p xml:id="_720b8">Procédé conforme à l'une des revendications 1 à 3, dans lequel on récupère le composé de formule (I) sous la forme d'un sel de métal ou d'addition d'acide, admissible en pharmacie, ou l'on transforme ultérieurement ce composé en un tel sel. </p>
			</div>
			<div n="5" type="claim">
				<p xml:id="_ba52c">Procédé conforme à l'une des revendications 1 à 4, dans lequel, dans lesdites formules, A représente un chaínon -S- et B représente un chaínon -CH=. </p>
			</div>
			<div n="6" type="claim">
				<p xml:id="_325be">Procédé conforme à l'une des revendications 1 à 4, mis en oeuvre pour préparer du 4-(n-butyl)-4,5-dihydro-7-hydroxy-5-oxo-N-(4-pyridyl)thiéno[3,2-b]pyridine6-carboxamide, ou un sel de métal ou d'addition d'acide, admissible en pharmacie, de ce composé. </p>
			</div>
			<div n="7" type="claim">
				<p xml:id="_8bc3e">Procédé conforme à l'une des revendications 1 à 6, qui comporte l'étape supplémentaire consistant à mélanger le composé de formule (I), après l'avoir éventuellement converti en un sel de métal ou d'addition d'acide, admissible en pharmacie, avec un véhicule ou un diluant admissible en pharmacie. </p>
			</div>
		</div>
		<div type="description" xml:lang="en"><p xml:id="_26616">This invention relates to thienopyridine derivatives which are useful as immunoregulators and for the prevention and treatment of osteoporosis and pharmaceutical preparations containing them. </p>
		<p xml:id="_d8e32">EP-A-0 059 698 discloses carboxamide compounds that apparently enhance cell-mediated immunity. These compounds are cyclic and include a benzene ring. </p><p xml:id="_f9798">Thienopyridine derivatives represented by Formula (A), possess the 4-hydroxythieno[2,3-b]pyridin-6-one skeleton and are described in J. Chem. Res. (S), 214 (1985) and J. Chem. Res. (S),122 (1986):  
wherein Ro represents hydrogen or methyl and Y represents hydrogen or ethoxycarbonyl. </p>
		<p xml:id="_1a211">Furthermore, thienopyridine derivatives represented by Formula (B), possess the 7-hydroxythieno[3,2-b]-pyridin-5-one skeleton, and are described in J. Chem. Res. (S), 6 (1980) and J. Chem. Res. (S), 84 (1984):  
wherein Ro represents hydrogen or methyl and Y represents hydrogen, ethoxycarbonyl, nitrile, acetyl or the like. </p>
		<p xml:id="_86caa">In compounds (A) and (B), their pharmacological activities are unknown. </p>
		<p xml:id="_a109d">The present invention relates to thienopyridine derivatives [hereinafter referred to as Compound (I)] represented by formula (I): 
wherein one of A and B represents -S-, and the other represents -CH=; R represents hydrogen or lower alkyl, and Z represents pyridyl; or a pharmaceutically acceptable salt thereof. </p>
		<p xml:id="_7c3b0">In the definition of each group in formula (I), the lower alkyl means a straight or branched alkyl having <measure type="interval"><num atLeast="1">1</num> to <num atMost="6">6</num></measure> carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, etc. </p>
		<p xml:id="_b5202">The pharmaceutically acceptable salt of Compound (I) includes acid addition salts, metal salts, etc. The acid addition salt includes, for example, an inorganic acid salt such as hydrochloride, sulfate, phosphate, etc.; an organic acid salt such as acetate, maleate, fumarate, tartarate, citrate, etc. The metal salt includes for  example, salts of alkali metal such as sodium, potassium, etc., salts of alkaline earth metal such as magnesium, calcium, etc.; aluminum salts, zinc salts and the like. </p>
		<p xml:id="_eae01">Next, a process for preparing Compound (I) is described. </p>
		<p xml:id="_fa5de">In the process shown below, in cases where the defined group(s) change under the conditions or are inappropriate for the practice of the process, the process can be easily operated by applying thereto means conventionally used in organic synthetic chemistry, for example, protection of functional groups, removal of protective groups, etc. </p>
		<p xml:id="_8050c">Compound (I) may be obtained by reacting Compound (II) represented by formula (II): 
wherein L represents a leaving group; and A, B and R have the same significance as described above, with Compound (III) represented by formula (III): H2N - Z 
wherein Z has the same significance as described above, preferably in the presence of a base. </p>
		<p xml:id="_4983d">Herein as the leaving group denoted by L, halogen such as chlorine, bromine, iodine, etc.; alkoxy such as 	methoxy, ethoxy, etc.; aryloxy such as phenoxy, etc.; alkanoyloxy such as propionyloxy, etc.; aroyloxy such as benzoyloxy, etc. are used.</p>
		<p xml:id="_c1ac2">As the base, alkali metal bicarbonates such as sodium bicarbonate, potassium bicarbonate, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; alkali metal hydrides such as sodium hydride, etc.; alkali metal alkoxides such as sodium methoxide, sodium ethoxide, etc.; alkali metal salts such as butyl lithium, etc. are used. </p>
		<p xml:id="_90807">As the solvent used in the reaction, any solvent may be usable, as long as it is inert to the reaction. For example, ethers such as tetrahydrofuran, dioxane, etc.; amides such as dimethylformamide, dimethylacetamide, etc.; ketones such as acetone, methyl ethyl ketone, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane, etc.; esters such as ethyl acetate, etc.; aromatic hydrocarbons such as benzene, toluene, xylene, etc.; dimethylsulfoxide and the like may be used singly or in combination. </p>
		<p xml:id="_722d2">The reaction is carried out at <measure type="interval"><num atLeast="-30">-30</num> to <num atMost="200">200</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>, preferably <measure type="interval"><num atLeast="-10">-10</num> to <num atMost="100">100</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> and generally completed in <measure type="interval"><num>30</num> <measure type="TIME" unit="min">minutes</measure> to <num>20</num> <measure type="TIME" unit="h">hours</measure></measure>. </p>
		<p xml:id="_be8ea">The starting compound (II) can be synthesized by known methods [J. Chem. Res. (S), 6 (1980); ibid., 84 (1984); ibid., 214 (1985); J. Chem. Res. (M), 113 (1980); ibid., 771 (1984); ibid., 2501 (1985)] or by a modified method of these methods. </p>
		<p xml:id="_f7c8a">The desired product in the process described above can be isolated and purified by means of purification conventionally used in organic synthetic chemistry, for example, by filtration, extraction, washing, drying, concentration, recrystallization, various chromatographies, etc. </p>
		<p xml:id="_8dcbd">Where it is desired to obtain the salts of Compound (I), Compound (I) may be purified as it is in case that Compound (I) is obtained in the form of its salt. In case that Compound (I) is obtained in its free form, Compound (I) is dissolved or suspended in an appropriate solvent and an appropriate acid or base is added to the solution or suspension to form its salts. </p>
		<p xml:id="_fd512">Compound (I) and a pharmaceutically acceptable salt thereof may also be present in the form of addition products with water or various solvents. These addition products are also included in the present invention. </p>
		<p xml:id="_291e9">Furthermore Compound (I) includes all possible steric isomers and mixtures thereof. </p>
		<p xml:id="_c6e41">Specific examples of Compound (I) obtained by the process described above are shown in Tables 1 and 2.</p>
		<p xml:id="_6a299">Next, the immunoregulating activity, activity of inhibiting bone absorption and acute toxicity of Compound (I) are described by referring to test examples. </p>
		<head xml:id="_69385">Test Example 1 Plaque Forming Cell Assay</head>
		<p xml:id="_dad17">The methods developed by Jerne [Science, 140, 405 (1963)] and Yamamoto, et al[Drugs. Exptl. Clin. Res., 8, 5 (1982)] were modified for plaque forming cell assay. </p>
		<p xml:id="_d6730">That is, Balb/c strain male mice (age of 7 weeks, Charles River Japan Inc.) were sensitized with <measure type="value"><num>1 x 108</num></measure> sheep red blood cells (Bio Test Research Institute) and the spleen was extirpated on the <measure type="list"><num>sixth</num> or <num>seventh</num> <measure type="TIME" unit="day">day</measure></measure>. The cells obtained from the spleen were treated with ACT solution (Tris-ammonium chloride isotonic buffer) to remove red blood cells. The cells were washed <measure type="value"><num>three</num></measure> times with RPMI1640 medium (Nissui Pharmaceutical Co.). The cells (<measure type="value"><num>1 x107</num></measure>) were incubated in RPMI-1640 medium containing <measure type="value"><num>10</num><measure type="FRACTION" unit="%">%</measure></measure> calf fetal serum (Gibco Co.), <measure type="value"><num>50</num> <measure type="DENSITY" unit="µg.ml⁻¹">µg/ml</measure></measure> streptomycin, <measure type="value"><num>50</num> <measure type="DENSITY" unit="IU.ml⁻¹">IU/ml</measure></measure> of penicillin, 2-mercaptoethanol (<measure type="value"><num>5 x 10-5</num> <measure type="DENSITY" unit="molarity">M</measure></measure>), sheep red blood cells (<measure type="value"><num>5 x 106</num></measure> cells) and a test compound dissolved in dimethyl sulfoxide supplied on a microculture plate (NUNC Co., 24 wells) in a carbon dioxide gas incubator (TABAI ESPEC CORP) at <measure type="value"><num>37</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num>5</num> <measure type="TIME" unit="day">days</measure></measure>. </p><p xml:id="_a8041">After completion of the incubation, the cells were transferred to a plastic test tube and centrifuged at <measure type="value"><num>2000</num> <measure type="FREQUENCY" unit="rpm">rpm</measure></measure>. After the supernatant was removed, the cells were resuspended in <measure type="value"><num>1</num> <measure type="MASS" unit="ml">ml</measure></measure> of RPMI-1640 medium. The cell suspension was sealed in a Cunnigham chamber (Takahashi Giken Co.) together with sheep red blood cells and guinea pig complement (Cedarlane Research Institute) according to the method of Cunnigham [Immunology, 14, 599 (1968)] and incubated at <measure type="value"><num>37</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="interval"><num atLeast="1">1</num> to <num atMost="2">2</num> <measure type="TIME" unit="h">hours</measure></measure>. Direct plaque forming cell (PFC) count was counted. </p>
		<p xml:id="_d1901">A rate of inhibiting antibody production by the test compound was determined by the following equation. Inhibition rate (%) = A - BA x 100 A :PFC count in the absence of test compound (dimethylsulfoxide alone) B :PFC count in the presence of test compound </p>
		<p xml:id="_daaa2">The results are shown in Table 3.
			<figure><table cols="4"><row><cell>Compound No. </cell><cell>Concentration (M) </cell><cell>Direct PFC Count (mean ± S.E.M.) </cell><cell>Inhibition Rate (%) </cell></row><row><cell>Control</cell><cell/><cell>5023 ± 38 </cell></row><row><cell>3</cell><cell>10-4</cell><cell>101 ± 76</cell><cell>98.0 </cell></row><row><cell/><cell>10-5</cell><cell>59 ± 38</cell><cell>98.8 </cell></row><row><cell>4</cell><cell>10-4</cell><cell>336 ± 124</cell><cell>93.3 </cell></row><row><cell/><cell>10-5</cell><cell>395 ± 52</cell><cell>92.1 </cell></row><row><cell>5</cell><cell>10-4</cell><cell>109 ± 77</cell><cell>97.8 </cell></row><row><cell/><cell>10-5</cell><cell>227 ± 131</cell><cell>95.5 </cell></row><row><cell>6</cell><cell>10-4</cell><cell>42 ± 29</cell><cell>99.2 </cell></row><row><cell/><cell>10-5</cell><cell>59 ± 29</cell><cell>98.8 </cell></row></table></figure>
		</p>
		<p xml:id="_edb87">Autoimmune diseases such as chronic articular rheumatism or the like are considered to result from tissue injury due to accentuation of B cells as the result of hypofunction of T cells. It is thus expected that Compound (I) would be effective against autoimmune disease by inhibiting antibody production. </p>
		<head xml:id="_a7e8b">Test Example 2 Activity of inhibiting bone absorption</head>
		<p xml:id="_c9836">A calvaria of a <measure type="interval"><num atLeast="5">5</num> to <num atMost="6">6</num> <measure type="TIME" unit="day">day</measure></measure>-old dd mouse was aseptically cut off, washed with Dulbecco's modified phosphate buffered saline not containing calcium and magnesium (manufactured by Gibco Oriental Co.) and separated along the sutura of its center. One half of the calvaria so separated was cultured in <measure type="value"><num>1.5</num> <measure type="VOLUME">ml</measure></measure> of Dulbecco's modified Eagle medium (manufactured by Gibco Oriental Co.) containing <measure type="value"><num>15</num><measure type="FRACTION" unit="%">%</measure></measure> of thermally inactivated (at <measure type="value"><num>56</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num>2</num> <measure type="TIME" unit="min">minutes</measure></measure>) horse serum and <measure type="value"><num>2.5</num><measure type="FRACTION" unit="%">%</measure></measure> of fetal calf serum. The test compound was dissolved in dimethyl sulfoxide, and <measure type="value"><num>10</num> <measure type="VOLUME" unit="µl">µl</measure></measure> (final concentration: <measure type="value"><num>1 x 10-4</num> <measure type="CONCENTRATION" unit="molarity">M</measure></measure> or <measure type="value"><num>1 x 10-5</num> <measure type="CONCENTRATION" unit="molarity">M</measure></measure>) of the solution so prepared was added to the culture. Parathyroid hormone (human PTH 1-34, manufactured by Sigma Co.) was dissolved in <measure type="value"><num>0.15</num> <measure type="CONCENTRATION" unit="molarity">M</measure></measure> sodium chloride solution (<measure type="value"><measure type="ACIDITY" scale="pH">pH</measure> <num>3</num></measure>), and <measure type="value"><num>3</num> <measure type="VOLUME">µl</measure></measure> (final concentration: <measure type="value"><num>1 x 10-8</num> <measure type="CONCENTRATION" unit="molarity">M</measure></measure>) of the solution so prepared was added to the culture. The cultivation was carried out for <measure type="value"><num>96</num> <measure type="TIME" unit="h">hours</measure></measure> at <measure type="value"><num>37</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> in an atmosphere consisting of <measure type="value"><num>95</num><measure type="FRACTION" unit="%">%</measure></measure> of air and <measure type="value"><num>5</num><measure type="FRACTION" unit="%">%</measure></measure> of carbon dioxide. The culture medium was once replaced with a fresh one after <measure type="value"><num>48</num> <measure type="TIME" unit="h">hours</measure></measure> from the beginning of the cultivation. The concentration of dissolved calcium (i.e., absorption of bone) from the PTH-intensified bone was determined by measuring the quantity of calcium accumulated in the culture collected in <measure type="value"><num>96</num> <measure type="TIME" unit="h">hours</measure></measure> of cultivation, whereby the concentration of total calcium contained in the culture was measured with Calcium C-Test Wako (manufactured by Wako Pure Chemicals Co., Ltd.), and the inhibition rate was calculated therefrom in accordance with the equation set forth below. The results are shown in Table 4. Inhibition rate (%) = Cp - CdCp - Co x 100 Cd :Total calcium concentration in the culture treated with both test compound and PTH Cp :Total calcium concentration in the culture treated with PTH alone Co :Total calcium concentration in the culture treated with neither test compound nor PTH
			<figure><table cols="3"><row><cell>Compound No. </cell><cell>Concentration (µM) </cell><cell>Inhibition Rate (%) </cell></row><row><cell>1</cell><cell>100</cell><cell>-1 </cell></row><row><cell>2</cell><cell>100</cell><cell>51 </cell></row><row><cell>3</cell><cell>10</cell><cell>141 </cell></row><row><cell>4</cell><cell>10</cell><cell>58 </cell></row><row><cell>5</cell><cell>10</cell><cell>53 </cell></row><row><cell>6</cell><cell>10</cell><cell>38 </cell></row><row><cell>7</cell><cell>10</cell><cell>32 </cell></row><row><cell>8</cell><cell>10</cell><cell>18 </cell></row></table></figure>
		</p>
		<head xml:id="_b1c62">Test Example 3 Acute toxicity test</head>
		<p xml:id="_b7e8b">A test compound was orally administered to <measure type="value"><num>three</num></measure> dd-strain male mice weighing <measure type="interval"><num type="base">20</num> ± <num type="range">1</num> <measure type="MASS" unit="g">g</measure></measure>. The minimum lethal dose (MLD) was determined by observing the mortality for <measure type="value"><num>7</num> <measure type="TIME" unit="day">days</measure></measure> after the administration. </p><p xml:id="_d10b5">The results are shown in Table 5.
			<figure><table cols="2"><row><cell>Compound No. </cell><cell>MLD (mg/kg) </cell></row><row><cell>4</cell><cell>&gt; 300 </cell></row><row><cell>7</cell><cell>&gt; 300 </cell></row></table></figure>
		</p>
		<p xml:id="_37c9c">Compound (I) or a pharmaceutically acceptable salt thereof may be used as it is, or in various pharmaceutical forms. The pharmaceutical composition of the present invention can be prepared by uniformly mixing an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof as the active ingredient with pharmaceutically acceptable carriers. The pharmaceutical compositions are desirably in a single dose unit suited for oral or parenteral administration. </p>
		<p xml:id="_17b5c">In preparing the composition suited for oral administration, any pharmaceutically acceptable carrier may be used. Liquid preparations suited for oral administration, for example, a suspension and a syrup can be prepared using water; sugars such as sucrose, sorbitol, fructose, etc.; glycols such as polyethylene glycol, propylene glycol, etc.; oils such as sesame oil, olive oil, soybean oil, etc.; antiseptics such as p-hydroxybenzoic acid ester, etc.; flavors such as strawberry flavor, pepper mint, etc. Further a capsule, a tablet, a powder and a granule can be prepared using an excipient such as lactose, glucose, sucrose, mannitol, etc.; a disintegrator such as starch, sodium alginate, etc.; a lubricant such as magnesium stearate, talc, etc.; a binder such as polyvinyl alcohol, hydroxypropyl cellulose, gelatin, etc.; a surfactant such as a fatty acid ester, etc.; a plasticizer such as glycerine, etc. A tablet and a capsule are most useful single dose unit for oral administration because their administration is easy. </p> 
		<p xml:id="_764ac">Effective dose and number of administration of Compound (I) or a pharmaceutically acceptable salt thereof may vary depending upon modes of administration, age and body weight, conditions, etc. of a patient but it is generally preferred to administer Compound (I) in a dose of <measure type="interval"><num atLeast="1">1</num> to <num atMost="1000">1,000</num> <measure type="MASS" unit="mg">mg</measure></measure>/<measure type="value"><num>60</num> <measure type="MASS" unit="kg">kg</measure></measure> by dividing into <measure type="interval"><num atLeast="1">one</num> to <num atMost="4">four</num> times</measure>. 
		</p> 
		<p xml:id="_25607">The present invention is described by referring to Examples and Reference Examples below. </p> 
		<head xml:id="_8b59b">Example 1 </head>
		<head xml:id="_d3407">4,5-Dihydro-7-hydroxy-5-oxo-N-(3-pyridyl)thieno[3,2-b]pyridine-6-carboxamide (Compound 1)</head>
		<p xml:id="_72938">A mixture of <measure type="value"><num>2.43</num> <measure type="MASS" unit="g">g</measure></measure> (<measure type="value"><num>10.2</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of ethyl 4,5-dihydro-7-hydroxy-5-oxothieno[3,2-b]pyridine-6-carboxylate [J. Chem. Res. (S), 6 (1980); J. Chem. Res. (M), 113 (1980)], <measure type="value"><num>1.00</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>10.6</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of <measure type="value"><num>3</num></measure>-aminopyridine, <measure type="value"><num>50</num> <measure type="VOLUME" unit="ml">ml</measure></measure> of xylene and <measure type="value"><num>10</num> <measure type="VOLUME">ml</measure></measure> of dimethylformamide was heated at <measure type="value"><num>140</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num value="1">an</num> <measure type="TIME" unit="h">hour</measure></measure>. After completion of the reaction, insoluble matters were filtered and recrystallized from dimethylformamide to give <measure type="value"><num>1.56</num> <measure type="MASS">g</measure></measure> (yield: <measure type="value"><num>54</num><measure type="FRACTION" unit="%">%</measure></measure>) of Compound 1.
			<figure><table cols="4"><row><cell>Elemental analysis: C13H9N3O3S </cell></row><row><cell>Calcd. (%) :</cell><cell>C 54.35,</cell><cell>H 3.16,</cell><cell>N 14.63 </cell></row><row><cell>Found (%) :</cell><cell>C 54.11,</cell><cell>H 2.85,</cell><cell>N 14.48 </cell></row></table></figure>
IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure>:<num>3450</num>(br), <num>1638</num>, <num>1594</num>, <num>1547</num>, <num>1480</num>, <num>1408</num>, <num>1364</num>, <num>1264</num>, <num>1228</num>, <num>799</num>, <num>761</num></measure> 
NMR (CF3 CO2 D) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>9.79</num>(1H, s), <num>8.81</num>(1H, d, J= <measure type="value"><num>8.8</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.63</num>(1H, d, J=<measure type="value"><num>5.1</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.15</num>(1H, m), <num>8.10</num> (1H, d, J=<measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.28</num>(1H, d, J=<measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure></p>
		<head xml:id="_9a299">Example 2</head>
		<head xml:id="_e2133">4,5-Dihydro-7-hydroxy-5-oxo-N-(4-pyridyl)thieno[3,2-b]pyridine-6-carboxamide (Compound 2)</head>
		<p xml:id="_2196c">A mixture of <measure type="value"><num>2.48</num> <measure type="MASS" unit="g">g</measure></measure> (<measure type="value"><num>10.4</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of ethyl 4,5-dihydro-7-hydroxy-5-oxothieno[3,2-b]pyridine-6-carboxylate [J. Chem. Res. (S), 6 (1980); J. Chem. Res. (M), 113 (1980)], <measure type="value"><num>1.01</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>10.7</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of 4-aminopyridine, <measure type="value"><num>50</num> <measure type="VOLUME" unit="ml">ml</measure></measure> of xylene and <measure type="value"><num>10</num> <measure type="VOLUME">ml</measure></measure> of dimethylformamide was heated at <measure type="value"><num>140</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num value="1">an</num> <measure type="TIME" unit="h">hour</measure></measure>. After completion of the reaction, insoluble matters were filtered and tritylated with dimethylformamide with heating to give <measure type="value"><num>1.99</num> <measure type="MASS" unit="g">g</measure></measure> (yield: <measure type="value"><num>67</num><measure type="FRACTION" unit="%">%</measure></measure>) of Compound 2.
			<figure><table cols="4"><row><cell>Elemental analysis: C13H9N3O3S </cell></row><row><cell>Calcd. (%):</cell><cell>C 54.35,</cell><cell>H 3.16,</cell><cell>N 14.63 </cell></row><row><cell>Found (%):</cell><cell>C 54.31,</cell><cell>H 2.96,</cell><cell>N 14.45 </cell></row></table></figure>
IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure>:<num>3440</num>(br), <num>1662</num>, <num>1632</num>, <num>1575</num>, <num>1536</num>, <num>1498</num>, <num>1411</num>, <num>1370</num>, <num>1212</num>, <num>1006</num>, <num>826</num>, <num>751</num></measure>  
NMR (CF3 CO2 D) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>8.64</num>(2H, d, J=<measure type="value"><num>7.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.46</num>  (2H, d, J=<measure type="value"><num>7.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.11</num>(1H, d, J=<measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.27</num>(1H, d, J=<measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure></p>
		<head xml:id="_0839f">Example 3</head>
		<head xml:id="_8aa82">4-(n-butyl)-4,5-dihydro-7-hydroxy-5-oxo-N-(4-pyridyl)thieno[3,2-b]pyridine-6-carboxamide (Compound 3)</head>
		<p xml:id="_a13c5">A solution of <measure type="value"><num>1.18</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>4.00</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of the Compound a obtained in Reference Example 1, <measure type="value"><num>0.39</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>4.13</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of 4-aminopyridine and <measure type="value"><num>20</num> <measure type="VOLUME">ml</measure></measure> of toluene was heated to reflux for <measure type="value"><num>2</num> <measure type="TIME" unit="h">hours</measure></measure>. After cooling, the reaction mixture was poured into 1 N sodium hydroxide aqueous solution, and washed twice with chloroform. 2 N Hydrochloric acid aqueous solution was added to the aqueous layer and the precipitated white crystals were filtered and dried to give <measure type="value"><num>0.73</num> <measure type="MASS">g</measure></measure> (yield: <measure type="value"><num>53</num><measure type="FRACTION" unit="%">%</measure></measure>) of Compound 3. 
Melting point:<measure type="interval"><num atLeast="211.9">211.9</num>-<num atMost="216.5">216.5</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> 
MS (EI) m/e:343 (M+) IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure>:<num>3420</num>(br), <num>1661</num>, <num>1617</num>, <num>1591</num>, <num>1546</num>, <num>1509</num>, <num>1393</num>, <num>1196</num>, <num>796</num>, <num>758</num></measure> 
NMR (DMSO-d6) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):13.59(1H, s), 8.79(2H, d, J= <measure type="value"><num>6.6</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), 8.38(1H, d, J=<measure type="value"><num>5.1</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), 8.21(2H, d, J= <measure type="value"><num>6.6</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), 7.57(1H, d, J=<measure type="value"><num>5.1</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), 4.24(2H, t, J= <measure type="value"><num>7.6</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), 1.66(2H, m), 1.40(2H, m), 0.93(3H, t, J= <measure type="value"><num>7.1</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> </p>
		<head xml:id="_1b240">Example 4</head>
		<head xml:id="_40a1d">4-(n-butyl)-4,5-dihydro-7-hydroxy-5-oxo-N-(3-pyridyl)thieno[3,2-b]pyridine-6-carboxamide (Compound 4)</head>
		<p xml:id="_16455">Compound 4 was obtained (yield: <measure type="value"><num>72</num><measure type="FRACTION" unit="%">%</measure></measure>) in a manner similar to Example 3 except for using 3-aminopyridine in place of 4-aminopyridine. 
Melting point:<measure type="interval"><num atLeast="179.7">179.7</num> -<num atMost="182.6">182.6</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> 
MS (EI) m/e:343 (M+) IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure>:<num>3388</num>, <num>1627</num>, <num>1540</num>, <num>1390</num>, <num>798</num>, <num>770</num>, <num>668</num></measure> 
NMR (DMSO-d6) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>13.03</num>(1H, s), <num>9.20</num>(,1H, d, J= <measure type="value"><num>2.2</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.62</num>(1H, d, J=<measure type="value"><num>4.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.57</num>(1H, dd, J= <measure type="value"><num>2.2</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>, <measure type="value"><num>8.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.34</num>(1H, d, J=<measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.90</num>(,1H, dd, J=<measure type="value"><num>4.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>, <measure type="value"><num>8.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.55</num>(1H, d, J=<measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>4.24</num>(2H, t, J=<measure type="value"><num>7.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>1.65</num>(2H, m), <num>1.40</num>(2H, m), <num>0.93</num>(3H, t, J=<measure type="value"><num>7.3</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> </p>
		<head xml:id="_7f252">Example 5</head>
		<head xml:id="_ff3a3">7-(n-butyl)-6,7-dihydro-4-hydroxy-6-oxo-N-(4-pyridyl)thieno[2,3-b]pyridine-5-carboxamide (Compound 5)</head>
		<p xml:id="_3477c">Compound 5 was obtained (yield: <measure type="value"><num>78</num><measure type="FRACTION" unit="%">%</measure></measure>) in a manner similar to Example 3 except for using Compound b obtained in Reference Example 2 in place of Compound a. 
Melting point:<measure type="interval"><num atLeast="131.6">131.6</num> -<num atMost="139.4">139.4</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> 
MS (EI) m/e:343 (M+) IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure> :<num>2952</num>, <num>1614</num>, <num>1507</num>, <num>1380</num>, <num>1289</num>, <num>1229</num>, <num>1197</num>, <num>834</num>, <num>663</num></measure> 
NMR (DMSO-d6) δ<measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>13.34</num>(1H, s), <num>8.78</num>(2H, d, J= <measure type="value"><num>6.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.20</num>(2H, d, J=<measure type="value"><num>6.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.48</num>(1H, d, J= <measure type="value"><num>5.6</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.39</num>(1H, d, J=<measure type="value"><num>5.6</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>4.13</num>(2H, t, J= <measure type="value"><num>7.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>1.75</num>(2H, m), <num>1.41</num>(2H, m), <num>0.95</num>(3H, t, J=<measure type="value"><num>7.3</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> </p>
		<head xml:id="_34752">Example 6</head>
		<head xml:id="_afee5">7-(n-butyl)-6,7-dihydro-4-hydroxy-6-oxo-N-(3-pyridyl)thieno[2,3-b]pyridine-5-carboxamide (Compound 6)</head>
		<p xml:id="_ec4cc">Compound 6 was obtained (yield: <measure type="value"><num>76</num><measure type="FRACTION" unit="%">%</measure></measure>) in a manner similar to Example 3 except for using Compound b obtained in Reference Example 2 in place of Compound a and using 3-aminopyridine in place of 4-aminoyyridine. 
Melting point:<measure type="interval"><num atLeast="158.0">158.0</num> -<num atMost="158.4">158.4</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> 
MS (EI) m/e:343 (M+) IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure>:<num>1616</num>, <num>1585</num>, <num>1561</num>, <num>1542</num>, <num>1535</num>, <num>1482</num>, <num>752</num></measure> 
NMR (DMSO-d6) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>15.87</num>(1H, s), <num>12.49</num>(1H, s), <num>8.80</num>(1H, d, J=<measure type="value"><num>2.1</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.37</num>(1H, d, J=<measure type="value"><num>3.7</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.11</num> (1H, d, J=<measure type="value"><num>8.2</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="7.39">7.39</num>-<num atMost="7.44">7.44</num></measure>(1H, m), <num>7.42</num>(1H, d, J=<measure type="value"><num>5.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.35</num>(1H, d, J=<measure type="value"><num>5.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>4.10</num>(2H, t, J= <measure type="value"><num>7.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>1.74</num>(2H, m), <num>1.40</num>(2H, m), <num>0.95</num>(3H, t, J= <measure type="value"><num>7.3</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> </p>
		<head xml:id="_a0416">Example 7</head>
		<head xml:id="_06c8a">6,7-Dihydro-4-hydroxy-6-oxo-N-(4-pyridyl)thieno[2,3-b]pyridine-5-carboxamide (Compound 7)</head>
		<p xml:id="_d0354">Compound 7 was obtained (yield: <measure type="value"><num>58</num><measure type="FRACTION" unit="%">%</measure></measure>) in a manner similar to Example 3 except for using ethyl 6,7-dihydro-4-hydroxy-6-oxothieno[2,3-b]pyridine-5-carboxylate [J. Chem. Res. (S), 214 (1985)] in place of Compound a. 
Melting point:&gt;<measure type="value"><num>300</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> 
MS (EI) m/e:287 (M+) IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure>:<num>1660</num>, <num>1633</num>, <num>1573</num>, <num>1544</num>, <num>1487</num>, <num>1426</num>, <num>1356</num>, <num>1009</num>, <num>799</num>, <num>560</num>, <num>465</num></measure> 
NMR (DMSO-d6) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>15. 58</num> (1H, bs), <measure type="interval"><num atLeast="12.80">12. 80</num>-<num atMost="12.98">12. 98</num></measure> (2H, m), <num>8.51</num>(2H, d, J=<measure type="value"><num>6.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.64</num>(2H, d, J=<measure type="value"><num>6.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.29</num>(2H, s)</measure> </p>
		<head xml:id="_dc8eb">Example 8</head>
		<head xml:id="_dd0fa">6,7-Dihydro-4-hydroxy-6-oxo-N-(3-pyridyl)thieno[2,3-b]pyridine-5-carboxamide (Compound 8)</head>
		"><p xml:id="_7bb65">Compound 8 was obtained (yield: <measure type="value"><num>75</num><measure type="FRACTION" unit="%">%</measure></measure>) in a manner similar to Example 3 except for using ethyl 6,7-dihydro-4-hydroxy-6-oxothieno[2,3-b]pyridine-5-carboxylate [J. Chem. Res. (S), 214 (1985)] in place of Compound a, and using 3-aminopyridine in place of 4-aminopyridine.  
Melting point:<measure type="interval"><num atLeast="294.88">294.8 8</num> - <num atMost="295.9">295.9</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> 
MS (EI) m/e:287 (M+) IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure>:<num>1648</num>, <num>1601</num>, <num>1562</num>, <num>1482</num>, <num>1427</num>, <num>1356</num>, <num>1263</num>, <num>801</num>, <num>554</num>, <num>472</num></measure> 
NMR (DMSO-d6) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>15.85</num>(1H, s), <num>12.97</num>(1H, s), <num>12.61</num>(1H, s), <num>8.80</num>(1H, d, J=<measure type="value"><num>2.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.37</num>(1H, dd, J=<measure type="value"><num>1.1</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>, <measure type="value"><num>4.7</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="8.04">8.04</num>-<num atMost="8.13">8.13</num></measure>(1H, m), <num>7.42</num>(1H, dd, J=<measure type="value"><num>8.2</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>, <measure type="value"><num>4.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.29</num>(1H, d, J=<measure type="value"><num>4.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.29</num>(1H, dd, J=<measure type="value"><num>9.9</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>, <measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> </p>
		<head xml:id="_848db">Example 9 Tablet</head>
		<p xml:id="_b8b53">A tablet having the following ingredients is prepared in a conventional manner. 
			<figure><table cols="2"><row><cell>Compound 1</cell><cell><measure type="value"><num>50</num> <measure type="MASS">mg</measure></measure> </cell></row><row><cell>Lactose</cell><cell><measure type="value"><num>60</num> <measure type="MASS">mg</measure></measure> </cell></row><row><cell>Potato starch</cell><cell><measure type="value"><num>30</num> <measure type="MASS" unit="mg">mg</measure></measure> </cell></row><row><cell>Polyvinyl alcohol</cell><cell><measure type="value"><num>2</num> <measure type="MASS">mg</measure></measure> </cell></row><row><cell>Magnesium stearate</cell><cell><measure type="value"><num>1</num> <measure type="MASS">mg</measure></measure> </cell></row><row><cell>Tar pigment</cell><cell>trace </cell></row></table></figure>
		</p>
		<head xml:id="_9428c">Example 10 Syrup</head>
		<p xml:id="_9f9fe">A syrup preparation having the following ingredients is prepared in a conventional manner. 
			<figure><table cols="2"><row><cell>Compound 2</cell><cell><measure type="value"><num>50</num> <measure type="MASS">mg</measure></measure> </cell></row><row><cell>Refined sugar</cell><cell><measure type="value"><num>30</num> <measure type="MASS">mg</measure></measure> </cell></row><row><cell>Ethyl p-hydroxybenzoate</cell><cell><measure type="value"><num>40</num> <measure type="MASS">mg</measure></measure> </cell></row><row><cell>Propyl p-hydroxybenzoate</cell><cell><measure type="value"><num>10</num> <measure type="MASS">mg</measure></measure> </cell></row><row><cell>Strawberry flavor</cell><cell>0.1 cc </cell></row><row><cell>Water is added until the total volume is 100 cc. </cell></row></table></figure>
		</p>
		<head xml:id="_fe4c6">Reference Example 1</head>
		<head xml:id="_6eaa8">Ethyl 4-(n-butyl)-4,5-dihydro-7-hydroxy-5-oxothieno[3,2-b]pyridine-6-carboxylate (Compound a)</head>
		<p xml:id="_a1d3d">A) To a solution of <measure type="value"><num>15.7</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>0.100</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mol">mol</measure></measure>) of methyl 3-aminothiophene-2-carboxylate and <measure type="value"><num>15.2</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>0.110</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mol">mol</measure></measure>) of potassium carbonate in <measure type="value"><num>200</num> <measure type="VOLUME">ml</measure></measure> of dimethylformamide was added <measure type="value"><num>34.1</num> <measure type="VOLUME">ml</measure></measure> (<measure type="value"><num>0.300</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mol">mol</measure></measure>) of n-butyl iodide at <measure type="value"><num>25</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>. The mixture was stirred at <measure type="value"><num>120</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num>10</num> <measure type="TIME" unit="h">hours</measure></measure>. After cooling, the solvent was evaporated under reduced pressure and <measure type="value"><num>200</num> <measure type="VOLUME">ml</measure></measure> of ethyl acetate was added to the residue. An inorganic salt was removed by filtration. The filtrate was again concentrated under reduced pressure. The residue was purified acetate/n-hexane = 1/9 v/v) to give <measure type="value"><num>10.2</num> <measure type="MASS">g</measure></measure> (yield: <measure type="value"><num>48</num><measure type="FRACTION" unit="%">%</measure></measure>) of methyl 3-(n-butylaminothiophene-2-carboxylate (Compound a-1). 
NMR (CDCl3) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>7.35</num>(1H, d, J=<measure type="value"><num>5.3</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="7.01">7.01</num>-<num atMost="7.30">7.30</num></measure> (1H, br), <num>6.98</num>(1H, d, J=<measure type="value"><num>5.3</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>3.83</num>(3H, s), <num>3.28</num> (2H, m), <measure type="interval"><num atLeast="1.21">1.21</num>-<num atMost="1.88">1.88</num></measure>(4H, m), <num>0.95</num>(3H, t, J=<measure type="value"><num>7.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> 
B) <measure type="value"><num>10.0</num> <measure type="MASS" unit="g">g</measure></measure> (<measure type="value"><num>46.9</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of Compound a-1 was dissolved in a solvent mixture of <measure type="value"><num>90</num> <measure type="VOLUME">ml</measure></measure> of 1,2-dichloroethane and <measure type="value"><num>9</num> <measure type="VOLUME" unit="ml">ml</measure></measure> of 1,4-dioxane. <measure type="value"><num>16.9</num> <measure type="VOLUME" unit="ml">ml</measure></measure> (<measure type="value"><num>0.141</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mol">mol</measure></measure>) of trichloromethyl chloroformate was dropwise added to the solution at <measure type="value"><num>25</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure>. The mixture was stirred at <measure type="value"><num>75</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num>7</num> <measure type="TIME" unit="h">hours</measure></measure>. After cooling, <measure type="value"><num>0.50</num> <measure type="MASS" unit="g">g</measure></measure> of activated carbon was added to the reaction mixture followed by reflux for <measure type="value"><num>an</num> <measure type="TIME" unit="h">hour</measure></measure> in a nitrogen flow. After cooling, activated carbon was removed by filtration. The filtrate was concentrated under reduced pressure and <measure type="value"><num>15</num> <measure type="VOLUME" unit="ml">ml</measure></measure> of ethyl acetate and <measure type="value"><num>50</num> <measure type="VOLUME" unit="ml">ml</measure></measure> of n-hexane were added to the residue. The mixture was then stirred. The precipitated white crystals were filtered and dried to give <measure type="value"><num>6.96</num> <measure type="MASS" unit="g">g</measure></measure> (yield: <measure type="value"><num>66</num><measure type="FRACTION" unit="%">%</measure></measure>) of 4-(n-butyl)-5H-thieno[3,2-d]oxazine-5,7(4H)-dione (Compound a-2).
NMR (CDCl3) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>7.95</num>(1H, d, J=<measure type="value"><num>5.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>6.97</num>(1H, d, J=<measure type="value"><num>5.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>4.01</num>(2H, t, J=<measure type="value"><num>7.2</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="1.17">1.17</num>-<num atMost="1.98">1.98</num></measure>(4H, m), <num>0.98</num>(3H, t, J=<measure type="value"><num>7.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> 
C) Under ice cooling, <measure type="value"><num>552</num> <measure type="MASS" unit="mg">mg</measure></measure> (<measure type="value"><num>24.0</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of sodium hydride was added to <measure type="value"><num>67.4</num> <measure type="VOLUME" unit="ml">ml</measure></measure> (<measure type="value"><num>0.444</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mol">mol</measure></measure>) of ethyl malonate. The mixture was stirred at <measure type="value"><num>25</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num>30</num> <measure type="TIME" unit="min">minutes</measure></measure>. To the solution mixture was added <measure type="value"><num>5.00</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>22.2</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of Compound a-2 and the mixture was stirred at <measure type="value"><num>150</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num>an</num> <measure type="TIME" unit="h">hour</measure></measure>. After cooling, <measure type="value"><num>300</num> <measure type="VOLUME" unit="ml">ml</measure></measure> of water was added to the reaction mixture. The mixture was washed twice with chloroform and 6 N hydrochloric acid aqueous solution was added to the aqueous layer. The precipitated crystals were filtered and 	dried to give <measure type="value"><num>3.33</num> <measure type="MASS" unit="g">g</measure></measure> (yield: <measure type="value"><num>51</num><measure type="FRACTION" unit="%">%</measure></measure>) of Compound a.
NMR (CDCl3) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>7.69</num>(1H, d, J=<measure type="value"><num>5.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.02</num>(1H, d, J=<measure type="value"><num>5.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>4.18</num>(2H, q, J=<measure type="value"><num>7.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>3.64</num>(2H, t, J= <measure type="value"><num>7.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="1.08">1.08</num>-<num atMost="1.76">1.76</num></measure>(4H, m), <num>1.22</num>(3H, t, J=<measure type="value"><num>7.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>),</measure> </p>
		<head>(Compound b)</head>
		<p xml:id="_b5615">A) Methyl 2-butyl(n-)aminothiophene-3-carboxylate (Compound b-1) was obtained (yield: <measure type="value"><num>23</num><measure type="FRACTION" unit="%">%</measure></measure>) in a manner similar to Reference Example 1,A) step except for using methyl 2-amino-3-thiopenecarboxylate [Chem. Ber., 98, 3571 (1965)] in place of methyl 3-aminothiophene-2-carboxylate. 
NMR (CDCl3) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<measure type="interval"><num atLeast="7.08">7.08</num>-<num atMost="7.38">7,38</num></measure>(1H, br), <num>7.03</num>(1H, d, J=<measure type="value"><num>5.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>6.14</num>(1H, d, J=<measure type="value"><num>5.5</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>3.83</num>(3H, s), <num>3.23</num> (2H, q, J=<measure type="value"><num>6.2</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="1.22">1.22</num>-<num atMost="1.90">1.90</num></measure>(4H, m), <num>0.96</num>(3H, t, J=<measure type="value"><num>7.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> 
B) 7-(N-butyl)-6H-thieno[2,3-d]oxazine-4,6(7H)-dione (Compound b-2) was obtained (yield: <measure type="value"><num>80</num><measure type="FRACTION" unit="%">%</measure></measure>) in a manner similar to Reference Example 1,B) step except for using Compound b-1 in place of Compound a-1. 
NMR (CDCl3) δ<measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>7.59</num>(1H, d, J=<measure type="value"><num>5.2</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>6.30</num>(1H, d, J=<measure type="value"><num>5.2</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>3.97</num>(2H, t, J=<measure type="value"><num>7.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="1.15">1.15</num>-<num atMost="1.93">1.93</num></measure>(4H, m), <num>0.96</num>(3H, t, J=<measure type="value"><num>7.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> 
C) Compound b was obtained (yield: <measure type="value"><num>92</num><measure type="FRACTION" unit="%">%</measure></measure>) in a manner  similar to Reference Example 1,C) step except for using Compound b-2 in place of Compound a-2. 
NMR (DMSO-d6) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>7.34</num>(1H, d, J=<measure type="value"><num>5.7</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.29</num>(1H, d, J=<measure type="value"><num>5.7</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>4.32</num>(2H, q, J=<measure type="value"><num>7.0</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>3.97</num>(2H, t, J=<measure type="value"><num>7.3</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="1.60">1.60</num>-<num atMost="1.71">1.71</num></measure>L2H, m), <num>1.30</num>(3H, t, J=<measure type="value"><num>7.1</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <measure type="interval"><num atLeast="1.26">1.26</num>-<num atMost="1.40">1.40</num></measure>(2H, m), <num>0.92</num>(3H, t, J=<measure type="value"><num>7.3</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure> </p>
							</div>
						</body>
					</text>
				</group>
			</text>
		</TEI>
	</teiCorpus>
</teiCorpus>
